日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Natalizumab improves ambulation in relapsing-remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM

纳他珠单抗可改善复发缓解型多发性硬化症患者的步行能力:前瞻性 TIMER 研究的结果和 AFFIRM 研究的回顾性分析

Voloshyna, N; Havrdová, E; Hutchinson, M; Nehrych, T; You, X; Belachew, S; Hotermans, C; Paes, D

How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?

芬戈莫德(gilenya®)在高度活跃的复发缓解型多发性硬化症的治疗方案中扮演什么角色?

Fazekas, Franz; Bajenaru, Ovidiu; Berger, Thomas; Fabjan, Tanja Hojs; Ledinek, Alenka Horvat; Jakab, Gábor; Komoly, Samuel; Kobys, Tetiana; Kraus, Jörg; Kurča, Egon; Kyriakides, Theodoros; Lisý, L'ubomír; Milanov, Ivan; Nehrych, Tetyana; Moskovko, Sergii; Panayiotou, Panayiotis; Jazbec, Saša Šega; Sokolova, Larysa; Taláb, Radomír; Traykov, Latchezar; Turčáni, Peter; Vass, Karl; Vella, Norbert; Voloshyná, Nataliya; Havrdová, Eva